Xiao Kang-Wen, Yang Zhi-Qiang, Yan Xin, Liu Zhi-Bo, Yang Min, Guo Liang-Yu, Cai Lin
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Front Bioeng Biotechnol. 2022 Apr 19;10:846812. doi: 10.3389/fbioe.2022.846812. eCollection 2022.
N6-methyladenosine (m6A) methylation played a key role in tumor growth. However, the relationship between m6A and soft tissue sarcoma (STS) was still unclear. The characterization and patterns of m6A modification in STS (TCGA-SARC and GSE17674) were analyzed comprehensively through bioinformatics and real-time polymerase chain reaction (RT-PCR). The effects of different m6A modification patterns on prognosis and immune infiltration of STS were further explored. Differentially expressed gene (DEG) analysis was performed. Moreover, an m6Ascore was constructed by principal component analysis (PCA). In addition, two immunotherapy datasets (IMvigor210 and GSE78220) and a sarcoma dataset (GSE17618) were used to evaluate the m6Ascore. Huge differences were found in somatic mutation, CNV, and expression of 25 m6A regulators in STS. Two modification patterns (A and B) in STS were further identified and the m6A cluster A showed a better clinical outcome with a lower immune/stromal score compared with the m6A cluster B ( < 0.050).In addition to , most STS samples from m6A cluster A showed a high m6Ascore, which was related to mismatch repair and a better prognosis of STS ( < 0.001). In contrast, the m6A cluster B, characterized by a low m6Ascore, was related to the MYC signaling pathway, which led to a poor prognosis of STS. A high m6Ascore also contributed to a better outcome of PD-1/PD-L1 blockade immunotherapy. The modification patterns of 25 m6A regulators in the STS microenvironment were explored comprehensively. The novel m6Ascore effectively predicted the characteristics of the tumor microenvironment (TME) and outcome in STS and provided novel insights for future immunotherapy.
N6-甲基腺苷(m6A)甲基化在肿瘤生长中起关键作用。然而,m6A与软组织肉瘤(STS)之间的关系仍不清楚。通过生物信息学和实时聚合酶链反应(RT-PCR)全面分析了STS(TCGA-SARC和GSE17674)中m6A修饰的特征和模式。进一步探讨了不同m6A修饰模式对STS预后和免疫浸润的影响。进行了差异表达基因(DEG)分析。此外,通过主成分分析(PCA)构建了m6A评分。另外,使用两个免疫治疗数据集(IMvigor210和GSE78220)和一个肉瘤数据集(GSE17618)来评估m6A评分。在STS的体细胞突变、拷贝数变异(CNV)和25种m6A调节因子的表达方面发现了巨大差异。进一步确定了STS中的两种修饰模式(A和B),与m6A簇B相比,m6A簇A显示出更好的临床结果,免疫/基质评分更低(<0.050)。此外,来自m6A簇A的大多数STS样本显示出高m6A评分,这与错配修复和STS的较好预后相关(<0.001)。相比之下,以低m6A评分为特征的m6A簇B与MYC信号通路相关,这导致STS预后不良。高m6A评分也有助于PD-1/PD-L1阻断免疫治疗取得更好的效果。全面探索了STS微环境中25种m6A调节因子的修饰模式。新的m6A评分有效地预测了STS中肿瘤微环境(TME)的特征和结果,并为未来的免疫治疗提供了新的见解。